Patents by Inventor Richard D. Connell

Richard D. Connell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
    Patent number: 7087613
    Abstract: A method of monotherapy for a subject suffering from abnormal cell growth expressing the epidermal growth factor receptor (EGFR) which comprises orally administering to the subject a therapeutically effective amount of a crystalline polymorph of the hydrochloride salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine so as to treat the subject.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: August 8, 2006
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Timothy Norris, Jeffrey W. Raggon, Richard D. Connell, James D. Moyer, Michael J. Morin, Shama M. Kajiji, Barbara A. Foster, Karen J. Ferrante, Sandra L. Silberman
  • Sulfonamide substituted chroman derivatives
    Patent number: 6903218
    Abstract: This invention related to novel sulfonamide substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: June 7, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Gaetan H. Ladouceur, Richard D. Connell, Jeremy Baryza, Ann-Marie Campbell, Timothy G. Lease, James H. Cook
  • Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
    Patent number: 6900221
    Abstract: The present invention relates to a stable crystalline form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form, and its use. The invention also relates to the pharmaceutical compositions containing the stable polymorph B form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine as hydrochloride, as well other forms of the compound, and to methods of treating hyperproliferative disorders, such as cancer, by administering the compound.
    Type: Grant
    Filed: November 9, 2000
    Date of Patent: May 31, 2005
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Timothy Norris, Jeffrey W. Raggon, Richard D. Connell, James D. Moyer, Michael J. Morin, Shama M. Kajiji, Barbara A. Foster, Karen J. Ferrante, Sandra L. Silberman
  • Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
    Patent number: 6797714
    Abstract: This invention is related to novel carboxyl substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: September 28, 2004
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Richard D. Connell, Timothy G. Lease, Jeremy L. Baryza
  • Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
    Publication number: 20040072843
    Abstract: This invention related to novel sulfonamide substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.
    Type: Application
    Filed: September 19, 2003
    Publication date: April 15, 2004
    Inventors: Gaetan H. Ladouceur, Richard D. Connell, Jeremy Baryza, Ann-Marie Campbell, Timothy G. Lease, James H. Cook
  • Small molecules for the treatment of abnormal cell growth
    Publication number: 20030171386
    Abstract: This invention relates to small molecules that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such small molecules in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds. The invention further relates to small molecules that are selective for erbB2 receptor over the erbB1 receptor, wherein said erbB2 inhibitor has a range of selectivities for erbB2 over erbB1 between 50-1500.
    Type: Application
    Filed: December 10, 2002
    Publication date: September 11, 2003
    Applicant: Pfizer Inc.
    Inventors: Richard D. Connell, John C. Kath, James D. Moyer
  • Compounds useful for preparation of Beta-3 adrenoreceptor agonist
    Publication number: 20030073839
    Abstract: This invention related to novel sulfonamide substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.
    Type: Application
    Filed: March 7, 2000
    Publication date: April 17, 2003
    Inventors: Gaetan H. Ladouceur, Richard D. Connell, Jeremy Baryza, Anne-Marie Campbell, Timothy G. Lease, James H. Cook
  • Novel carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
    Publication number: 20030013705
    Abstract: This invention is related to novel carboxyl substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.
    Type: Application
    Filed: August 21, 2002
    Publication date: January 16, 2003
    Inventors: Richard D. Connell, Timothy G. Lease, Jeremy L. Baryza
  • Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
    Patent number: 6469031
    Abstract: This invention is related to novel carboxyl substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: October 22, 2002
    Assignee: Bayer Corporation
    Inventors: Richard D. Connell, Timothy G. Lease, Jeremy Baryza
  • Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
    Patent number: 6410792
    Abstract: Amide derivatives and methods of administering the compositions to mammals to treat disorders such as obesity that are mediated by NPY and especially those mediated by NPY via the Y5 receptor.
    Type: Grant
    Filed: April 20, 1999
    Date of Patent: June 25, 2002
    Assignee: Bayer Corporation
    Inventors: Richard D. Connell, Timothy G. Lease, Gaetan H. Ladouceur, Martin H. Osterhout
  • Methods and composition for restoring conformational stability of a protein of the p53 family
    Publication number: 20020048271
    Abstract: The invention is in the field of cancer treatment. In particular, the present invention provides pharmaceutical compounds capable of interacting with mutant and non-mutant forms of cancer-related regulatory proteins such that the mutant protein regains the capacitv to properly interact with other macromolecules thereby restoring or stabilizing all or a portion of its wild type activity. Regulatory proteins include members of the p53 protein family such as. for example, p53, p63 and p73. The compounds of the invention are useful for cancer treatment. Methods for screening for such pharmacological compounds are also provided.
    Type: Application
    Filed: May 23, 2001
    Publication date: April 25, 2002
    Inventors: Farzan Rastinejad, Barbara A. Foster, Heather A. Coffey, Richard D. Connell
  • NPY5 receptor antagonists and methods for using same
    Patent number: 6245817
    Abstract: &agr;-alkoxy and &agr;-thioalkoxyamide compositions and methods of administering the compositions to mammals to treat disorders such as obesity that are mediated by NPY and especially those mediated by NPY via the Y5 receptor.
    Type: Grant
    Filed: April 20, 1999
    Date of Patent: June 12, 2001
    Assignee: Bayer Corporation
    Inventors: Richard D. Connell, Timothy G. Lease, Gaetan H. Ladouceur, Martin H. Osterhout
  • Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
    Patent number: 6051586
    Abstract: This invention related to novel sulfonamide substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.
    Type: Grant
    Filed: November 23, 1998
    Date of Patent: April 18, 2000
    Assignee: Bayer Corporation
    Inventors: Gaetan H. Ladouceur, Richard D. Connell, Jeremy Baryza, Ann-Marie Campbell, Timothy G. Lease, James H. Cook
  • Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
    Patent number: 6048900
    Abstract: Amide derivatives and methods of administering the compositions to mammals to treat disorders such as obesity that are mediated by NPY and especially those mediated by NPY via the Y5 receptor.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: April 11, 2000
    Assignee: Bayer Corporation
    Inventors: Richard D. Connell, Timothy G. Lease, Gaetan H. Ladouceur, Martin H. Osterhout
  • NPY5 receptor antagonists and methods for using same
    Patent number: 5939462
    Abstract: .alpha.-alkoxy and .alpha.-thioalkoxyamide compositions and methods of administering the compositions to mammals to treat disorders such as obesity that are mediated by NPY and especially those mediated by NPY via the Y5 receptor.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: August 17, 1999
    Assignee: Bayer Corporation
    Inventors: Richard D. Connell, Timothy G. Lease, Gaetan H. Ladouceur, Martin H. Osterhout
  • Aminomethylene derivaties as immunosuppressants
    Patent number: 5686469
    Abstract: Compounds which suppress human T-lymphocyte proliferation are disclosed.
    Type: Grant
    Filed: December 12, 1995
    Date of Patent: November 11, 1997
    Assignee: Miles Inc.
    Inventors: Richard D. Connell, David G. Osterman, Michael E. Katz, Robert D. Dally
  • 2-oxoethyl derivatives as immunosuppressants
    Patent number: 5686424
    Abstract: A class of compounds that suppress human T-lymphocyte proliferation is disclosed.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: November 11, 1997
    Assignee: Miles Inc.
    Inventors: Richard D. Connell, David G. Osterman, Michael E. Katz
  • Sulfonamide aminomethylene derivatives as immunosuppressants
    Patent number: 5633277
    Abstract: Compounds which suppress human T-lymphocyte proliferation are disclosed.
    Type: Grant
    Filed: September 26, 1995
    Date of Patent: May 27, 1997
    Assignee: Miles Inc.
    Inventors: Richard D. Connell, David G. Osterman, Michael E. Katz, Robert D. Dally
  • Aminomethylene-peptides as immunosuppressants
    Patent number: 5385918
    Abstract: Compounds which suppress human T-lymphocyte proliferation are disclosed. The active compounds essentially contain at least the following structure: ##STR1## wherein A, R.sup.1, R.sup.2, R.sup.3, n, X.sup.1 and Z are defined in the specification.
    Type: Grant
    Filed: February 9, 1993
    Date of Patent: January 31, 1995
    Assignee: Miles Inc.
    Inventors: Richard D. Connell, David G. Osterman, Michael E. Katz, Rudolf Hanko, Stephan Schneider
  • Device for supplying air or medical gases in a conditioned, particularly a moistented and/or heated state to a patient
    Patent number: 5172686
    Abstract: A device for supplying air or medical gases in a conditioned, particularly a moistened and/or heated state to a patient, through an air pipe. The device includes at least one component to be connected to said air pipe, the component being formed by a cylinder-shaped element with an inner tube through which the moistened air flows, which cylinder-shaped element is fitted with self-regulating heating resistors which heat the air flowing through the tube, while the cylinder-shaped tube from one element at least is filled with a material which adsorbs or absorbs the water supplied by a water-supply line from a container, and has a good air-permeability.
    Type: Grant
    Filed: September 19, 1989
    Date of Patent: December 22, 1992
    Inventor: Jean-Michel Anthony